In 2021, Idaho had the highest death rate from skin cancer, with an estimated 2.8 people out of 100,000 dying from melanoma. This statistic shows the death rate for melanoma of the skin in the U.S. in 2021, by state, per 100,000 population.

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

In 2021, the death rate due to melanoma of the skin in the United States was two per 100,000 population. The maximum rate in the given period was 2.8 per 100,000 population. This statistic shows the death rate of melanoma of the skin in the United States from 1999 to 2021.

Mortality from skin cancers other than malignant melanoma (ICD-10 C44 equivalent to ICD-9 173). To reduce deaths from skin cancers other than malignant melanoma. Legacy unique identifier: P00653

In 2021, Utah had the highest rate of skin cancer, with an estimated 46 people out of 100,000 diagnosed with melanoma or another non-epithelial skin cancer. This statistic shows the incidence rate of skin cancer in the U.S. in 2021, by state, per 100,000 population.

Legacy unique identifier: P00645

Mortality from malignant melanoma (ICD-10 C43 equivalent to ICD-9 172). To reduce deaths from malignant melanoma. Legacy unique identifier: P00645

The rate of skin cancer in the United States increased for both sexes from 1999 to 2021, with the rate for males consistently higher than that of females. This statistic shows the incidence rate of skin cancer in the U.S. from 1999 to 2021, by gender, per 100,000 population.

As of 2021, non-Hispanic white people in the United States had the highest incidence rates of skin cancer among all races and ethnicities. Skin cancer is one of the most commonly occurring cancers in the world. Furthermore, the United States is among the countries with the highest rates of skin cancer worldwide. Skin cancer in the U.S. There are a few different types of skin cancer and some are more deadly than others. Basal and squamous skin cancers are more common and less dangerous than melanomas. Among U.S. residents, skin cancer has been demonstrated to be more prevalent among men than women. Skin cancer is also more prevalent among older adults. With treatment and early detection, skin cancers have a high survival rate. Fortunately, in recent years the U.S. has seen a reduction in the rate of death from melanoma. Skin cancer prevention Avoiding and protecting exposed skin from the sun (and other sources of UV light) is the primary means of preventing skin cancer. However, a survey of U.S. adults from 2024 found that around a third never used sunscreen.

Years of life lost due to mortality from malignant melanoma (ICD-10 C43). Years of life lost (YLL) is a measure of premature mortality. Its primary purpose is to compare the relative importance of different causes of premature death within a particular population and it can therefore be used by health planners to define priorities for the prevention of such deaths. It can also be used to compare the premature mortality experience of different populations for a particular cause of death. The concept of years of life lost is to estimate the length of time a person would have lived had they not died prematurely. By inherently including the age at which the death occurs, rather than just the fact of its occurrence, the calculation is an attempt to better quantify the burden, or impact, on society from the specified cause of mortality. Legacy unique identifier: P00274

BackgroundCutaneous melanoma (CM) is one of the most fatal types of skin cancer. Alarmingly, increases in incidence and mortality were noted globally for this malignancy, despite increase in understanding of melanoma pathogenesis and enhanced prevention efforts.MethodsData was extracted for CM patients for provinces and territories (except Quebec) using two independent, population-based registries. Analysis was performed using both clinical and pathological characteristics: tumor morphologic classification, age, sex, anatomic site affected and place of residence. Mortality trends were assessed over a 7-year period. Results were compared to prior findings for 1992–2010.ResultsDuring 2011–2017 39,610 patients were diagnosed with CM, with 5,890 reported deaths. National crude CM incidence was 20.75 (age-standardized incidence: 14.12) cases per 100,000 individuals per year. Females accounted for 45.8% of cases and 37.1% of deaths. While CM incidence rates continue to increase in both sexes, since 2013 the CM mortality is declining. We observed important differences across the provinces/territories, where Nova Scotia, Prince Edward Island, southern Ontario/British Columbia and certain coastal communities of New Brunswick demonstrated higher CM incidence and mortality rates. The observed incidence and mortality trends for 2011–2017 validate and extend earlier observations from 1992 to 2010 for CM.ConclusionThis population-based study highlights that while melanoma's incidence is increasing in Canada, mortality rates are for the first time decreasing since 2013. We detail regional distribution of this cancer highlighting communities in southern/coastal areas, as being most at risk as well as the latest trends of melanoma incidence by age, sex and anatomic site. In males, melanoma is more common on the head/trunk, while in females on the extremities. Notably, Acral Lentiginous Melanoma was the only CM subtype that was more common in females, which primarily affects hands and feet.

Non Melanoma Skin Cancer Market Outlook

The global non melanoma skin cancer market size was valued at USD 8.1 billion in 2023 and is expected to reach USD 14.7 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.8% during the forecast period. This market growth is largely driven by the increasing incidence of non melanoma skin cancers worldwide, advancements in treatment options, and rising awareness about early diagnosis and treatment.

One of the primary growth factors for the non melanoma skin cancer market is the escalating prevalence of skin cancers globally. Factors such as prolonged exposure to ultraviolet radiation from the sun and tanning beds, an aging population, and certain genetic predispositions contribute significantly to the rising incidence rates. Public health initiatives and campaigns have greatly increased awareness about the risks of UV exposure and the importance of protective measures, which in turn has driven demand for diagnostic and treatment services.

Technological advancements in the diagnosis and treatment of non melanoma skin cancers have also played a crucial role in market expansion. Innovations such as non-invasive imaging techniques, targeted therapies, and improved surgical methods have enhanced the efficacy and safety of treatments, making them more appealing to patients and healthcare providers. The development of photodynamic therapy and other less invasive treatments has further broadened the scope of available treatment options, thereby stimulating market growth.

The increasing investment in research and development activities by pharmaceutical companies, coupled with supportive governmental policies, has also been a significant driver for the market. Efforts to develop more effective medications and diagnostic tools have not only improved patient outcomes but have also expanded market opportunities. Additionally, the rising number of clinical trials and the approval of new drugs and treatments by regulatory bodies are expected to propel market growth further.

Mycosis Fungoides Treatment is gaining attention as part of the broader spectrum of therapies for skin-related malignancies. As a type of cutaneous T-cell lymphoma, Mycosis Fungoides requires specialized treatment approaches that often include topical therapies, phototherapy, and systemic treatments. The development of innovative therapeutic strategies, including targeted therapies and immunomodulatory agents, is crucial for improving patient outcomes. With ongoing research and clinical trials, there is a focus on enhancing the efficacy and safety of these treatments, which is expected to contribute to the overall growth of the skin cancer treatment market.

Regionally, North America holds a dominant position in the non melanoma skin cancer market, followed by Europe. The high prevalence of skin cancers in these regions, combined with advanced healthcare infrastructure and increased healthcare expenditure, contributes to their leading market shares. However, the Asia Pacific region is anticipated to witness the fastest growth during the forecast period due to improving healthcare infrastructure, increasing awareness, and rising disposable incomes.

Type Analysis

The non melanoma skin cancer market is categorized into different types, primarily including Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC), Merkel Cell Carcinoma, and others. Basal Cell Carcinoma is the most common type, accounting for approximately 80% of all non melanoma skin cancer cases. BCC is typically caused by long-term exposure to ultraviolet radiation, and its incidence is rising steadily. The relatively high survival rate and the less aggressive nature of BCC contribute to the larger market size of this segment.

Squamous Cell Carcinoma, the second most common type, accounts for about 20% of non melanoma skin cancers. SCC is more likely to grow deeper into skin layers and spread to other parts of the body compared to BCC, making it a significant focus for treatment advancements. The rising incidence of SCC, particularly among the aging population, is expected to drive the market growth for this segment. Treatment typically involves surgical removal, radiation therapy, and in some cases, systemic treatments.

Merkel Cell Carcinoma is a rare but aggressive form of non melanoma skin cancer. Its market share is relatively small compared to BCC and SCC, but due to it

Rate: Number of deaths due melanoma cancer per 100,000 Population.

Definition: Number of deaths per 100,000 with malignant melanoma of the skin as the underlying cause of death (ICD-10 code: C43).

Data Sources:

(1) Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File. CDC WONDER On-line Database accessed at http://wonder.cdc.gov/cmf-icd10.html

(2) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health

(3) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development

In 2021, there were 8,224 deaths in the United States due to melanoma of the skin. The highest number of deaths within the given period due to melanoma was reported in 2013, with 9,394 deaths. This statistic describes the number of deaths due to melanoma of the skin in the United States from 1999 to 2021.

Snapshot img

Precision Pathology For Cancer Market Size 2025-2029

The global precision pathology for cancer market is projected to see substantial growth, with an estimated market size and a CAGR of 8.2% during the forecast period. Access detailed market insights upon report purchase. The precision pathology for cancer market is being drives by the rising incidence of cancer and the subsequent demand for enhanced personalized therapies. Digital pathology, boosted by AI and machine learning, enhances diagnostic accuracy, accelerates diagnosis rates, and facilitates therapeutic recommendations, thereby significantly contributing to market expansion. Technological advancements, such as AI tools that improve diagnostic precision and treatment planning in cancer care, are also expected to fuel market growth. The increasing investments in research and development activities will further contribute to market expansion.

To access the full market forecast and comprehensive analysis, Buy Now

How is this market segmented?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in USD bn for the period 2025-2029, as well as historical data from 2019-2024 for the following segments:

Product

  Consumables
  Instruments


Technology

  Next-Generation Sequencing (NGS)
  Molecular Diagnostics
  Digital Pathology
  Artificial Intelligence (AI) and Machine Learning (ML)
  Liquid Biopsies
  Imaging Technologies


Applications

  Breast Cancer
  Lung Cancer
  Colorectal Cancers
  Prostate Cancer
  Melanoma And Non-Melanoma Skin Cancers


End-use

  Hospitals
  Diagnostic Laboratories
  Research Institutes


APAC

  China
  India
  Japan
  Australia
  Rest of APAC

Europe


  Germany
  Spain
  Italy
  UK
  Rest of Europe

North America


  US
  Canada

South America & MEA


  Brazil
  UAE
  South Africa
  Others





End-use

  Hospitals: Hospitals are key end-users, utilizing precision pathology for in-house diagnostics and treatment planning.
  Research Institutes: Research institutes use precision pathology for cancer research and development of new diagnostic and therapeutic strategies.
  Diagnostic Laboratories: Diagnostic laboratories provide precision pathology services to hospitals and other healthcare providers.


Product

  Consumables: This segment includes antibodies, kits & reagents, and probes used in precision pathology, driven by the increasing volume of diagnostic tests.
  Instruments: This segment encompasses slide staining systems, tissue processing systems, and PCR instruments, crucial for accurate pathological analysis.


Technology

  Liquid Biopsies: Liquid biopsies offer non-invasive methods for detecting cancer biomarkers, aiding in early diagnosis and treatment monitoring.
  Digital Pathology: Digital pathology solutions improve diagnostic accuracy and support therapeutic recommendations, enhancing overall efficiency.
  Imaging Technologies: Imaging technologies like CT, MRI, and ultrasound provide detailed anatomical and functional information for cancer diagnosis and treatment.
  Molecular Diagnostics: Molecular diagnostics are used to detect specific biomarkers and genetic mutations in cancer cells, facilitating targeted therapies.
  Next-Generation Sequencing (NGS): NGS technology is vital for genetic profiling of tumors, enabling personalized treatment strategies.
  Artificial Intelligence (AI) and Machine Learning (ML): AI and ML algorithms aid in analyzing complex pathological data, improving diagnostic precision and treatment planning.


Applications

  Lung Cancer: Genetic profiling helps in selecting appropriate treatments for different types of lung cancer.
  Breast Cancer: Precision pathology is critical in identifying specific subtypes of breast cancer, guiding targeted therapies.
  Prostate Cancer: Precision diagnostics help in determining the aggressiveness of prostate cancer and guiding treatment decisions.
  Colorectal Cancers: Precision pathology aids in identifying genetic mutations that influence treatment response in colorectal cancer.
  Melanoma And Non-Melanoma Skin Cancers: Molecular analysis assists in identifying specific mutations in skin cancers, enabling personalized therapies.

Regional Analysis

APAC: The Asia-Pacific (APAC) region is expected to experience rapid growth in the precision pathology for cancer market, driven by increasing healthcare expenditure, a rising prevalence of cancer, and growing awareness of precision medicine. China and India are key markets in APAC, with significant investments in healthcare infrastructure and a large patient pool, making them major hubs for precision pathology services.
Europe: Europe holds a substantial share of the precision pathology for cancer market, characterized by advanced healthcare systems, a strong focus on research and development, and a high adoption rate of advanc

This csv reports melanoma registration rates, per 100,000 population, by age. Age is grouped in 5 year segments (eg 0–4 years old, 5–9 years old). New Zealand and Australia have the world’s highest rates of melanoma, the most serious type of skin cancer. Melanoma is mainly caused by exposure to ultraviolet (UV) light, usually from the sun. New Zealand has naturally high UV levels, especially during summer.
The risk of developing melanoma is affected by factors such as skin colour and type, family history, and the amount of sun exposure. Melanoma can affect people at any age, but the chance of developing a melanoma increases with age. We report on age-standardised rates of melanoma to account for the increasing proportion of older people in our population. Our data on melanoma registrations come from the New Zealand Cancer Registry and the Ministry of Health's Mortality Collection. The passing of the Cancer Registry Act 1993 and Cancer Registry Regulations 1994 led to significant improvements in data quality and coverage (Ministry of Health, 2013). A sharp increase in registrations after 1993 is likely to have been related to these legislative and regulatory changes; for this reason we have only analysed data from 1996. 2014–15 data are provisional and subject to change. More information on this dataset and how it relates to our environmental reporting indicators and topics can be found in the attached data quality pdf.

In the years 2016 to 2020, over 99 percent of patients diagnosed with melanoma of the skin in England aged between 15 and 44 years of age would survive for at least one year, while patients this age had a five-year survival rate of nearly 97 percent. The survival rates for melanoma of the skin did generally fall if the patient was older when diagnosed.

This dataset presents the footprint of cancer mortality statistics in Australia for all cancers combined and the 6 top cancer groupings (colorectal, leukaemia, lung, lymphoma, melanoma of the skin and pancreas) and their respective ICD-10 codes. The data spans the years 2006-2010 and is aggregated to 2015 Department of Health Primary Health Network (PHN) areas, based on the 2011 Australian Statistical Geography Standard (ASGS).

Mortality data refer to the number of deaths due to cancer in a given time period. Cancer deaths data are sourced from the Australian Institute of Health and Welfare (AIHW) 2013 National Mortality Database (NMD).

For further information about this dataset, please visit:

• Australian Institute of Health and Welfare - Cancer Incidence and Mortality Across Regions (CIMAR) books.

• Australian Institute of Health and Welfare - 2013 National Mortality Database.

Please note:

• AURIN has spatially enabled the original data using the Department of Health - PHN Areas.

• Due to changes in geographic classifications over time, long-term trends are not available.

• Values assigned to "n.p." in the original data have been removed from the data.

• The Australian and jurisdictional totals include people who could not be assigned a PHN. The number of people who could not be assigned a PHN is less than 1% of the total.

• The Australian total also includes residents of Other Territories (Cocos (Keeling) Islands, Christmas Island and Jervis Bay Territory).

• Cause of Death Unit Record File data are provided to the AIHW by the Registries of Births, Deaths and Marriages and the National Coronial Information System (managed by the Victorian Department of Justice) and include cause of death coded by the Australian Bureau of Statistics (ABS). The data are maintained by the AIHW in the NMD.

• Year refers to year of occurrence of death for years up to and including 2012, and year of registration of death for 2013. Deaths registered in 2011 and earlier are based on the final version of cause of death data; deaths registered in 2012 and 2013 are based on revised and preliminary versions, respectively and are subject to further revision by the ABS.

• Cause of death information are based on underlying cause of death and are classified according to the International Classification of Diseases and Related Health Problems (ICD). Deaths registered in 1997 onwards are classified according to the 10th revision (ICD-10).

• Colorectal deaths presented are underestimates. For further information, refer to "Complexities in the measurement of bowel cancer in Australia" in Causes of Death, Australia (ABS cat. no. 3303.0).

This dataset presents the footprint of male cancer incidence statistics in Australia for all cancers combined and the 11 top cancer groupings (bladder, colorectal, head and neck, kidney, leukaemia, lung, lymphoma, melanoma of the skin, pancreas, prostate and stomach) and their respective ICD-10 codes. The data spans the years 2006-2010 and is aggregated to 2015 Department of Health Primary Health Network (PHN) areas, based on the 2011 Australian Statistical Geography Standard (ASGS).

Incidence data refer to the number of new cases of cancer diagnosed in a given time period. It does not refer to the number of people newly diagnosed (because one person can be diagnosed with more than one cancer in a year). Cancer incidence data come from the Australian Institute of Health and Welfare (AIHW) 2012 Australian Cancer Database (ACD).

For further information about this dataset, please visit:

• Australian Institute of Health and Welfare - Cancer Incidence and Mortality Across Regions (CIMAR) books.

• Australian Cancer Database 2012 Data Quality Statement.

Please note:

• AURIN has spatially enabled the original data using the Department of Health - PHN Areas.

• Due to changes in geographic classifications over time, long-term trends are not available.

• Values assigned to "n.p." in the original data have been removed from the data.

• The Australian and jurisdictional totals include people who could not be assigned a PHN. The number of people who could not be assigned a PHN is less than 1% of the total.

• The Australian total also includes residents of Other Territories (Cocos (Keeling) Islands, Christmas Island and Jervis Bay Territory).

• The ACD records all primary cancers except for basal and squamous cell carcinomas of the skin (BCCs and SCCs). These cancers are not notifiable diseases and are not collected by the state and territory cancer registries.

• The diseases coded to ICD-10 codes D45-D46, D47.1 and D47.3-D47.5, which cover most of the myelodysplastic and myeloproliferative cancers, were not considered cancer at the time the ICD-10 was first published and were not routinely registered by all Australian cancer registries. The ACD contains all cases of these cancers which were diagnosed from 1982 onwards and which have been registered but the collection is not considered complete until 2003 onwards.

• Note that the incidence data presented are for 2006-2010 because 2011 and 2012 data for NSW and ACT were not able to be provided for the 2012 ACD.

In 2022, Australia had the seventh-highest total number of skin cancer cases among women worldwide with 5,917, but the highest age-standardized rate. At that time, the age-standardized rate of skin cancer among women in Australia was around 29 per 100,000 population. This graph displays the rates of skin cancer in women in the countries with the highest total number of skin cancer cases among women worldwide in 2022.